Driving long-term value from biotech platform deals

One of the fastest growing investment areas in biotech is around enabling technologies and platforms, such as gene and cell therapies, antibody-drug conjugates(ADCs), RNA technologies and AI/ML applications. And with good reason, as a single platform deal has the potential to fuel a multitude of life-saving treatments.

In this panel, Mike Ward speaks with industry leaders from big pharma and Adaptimmune to discuss learnings from their technology partnerships and examine what factors help drive successful deals and long-term portfolio value.

  • Date:
    May 25, 2022
  • Start Time:
    10:00 am EDT
  • End Time:
    11:00 am EDT
  • Share: